Skip to main content
Fig. 1 | Radiation Oncology

Fig. 1

From: Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the ‘TOaSTT’ database

Fig. 1

a Overall survival of metastatic NSCLC patients receiving metastasis directed therapy (MDT) concurrent to targeted- or immunotherapy (TT/IT). b Progression free survival (PFS) of oligoprogressive disease (OPD) NSCLC patients receiving MDT concurrent to targeted- or immunotherapy (TT/IT). c Time to systemic therapy change (TTS) after MDT in in NSCLC patients receiving concurrent SRT and TT/IT. Blue line = OPD patients where a MDT of all present metastases (≤ 5 metastases) was performed. Yellow line = OPD patients where MDT of all progressive lesions was performed and all other metastases are controlled by TT/IT

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us